AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03848845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.
Study NCT03430804 — intervention group
Intervention type: OTHER
Intervention: Bishop score calculation of modified Bishop score in numbers by digital vaginal examination
Description: Measurement of cervical length by transvaginal ultrasound and digital examination of Bishop score in 320 parturients undergoing labour induction at term
Study NCT04111094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study NCT00589823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate release morphine sulphate
Description: drug dose as required by patient taken to treat up to four epsiodes of BTCP per day
Study NCT01262885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: 500 mg tablet, dose levels detailed in Arm description
Study NCT01379911 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt
Study NCT01379911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt
Study NCT01670331 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological preparation
Description: Session 1: Help patients understand their relationship to food. Patients complete a 'food diary' as 'homework'. Give information about lifestyle changes after surgery. Presents the model of 'stress' and how it influences 'overeating', to develop a more balanced lifestyle and better QoL.~Session 2: 'Intervention' using Compassion Focussed Therapy model to understand relationship to food from their diary. Help develop a 'minimising overeating plan' (a 'relapse prevention' plan). Help learn to meet needs in other ways than food.~Session 3: Focus on physical body. Current body image, explore hopes and expectations for after surgery. Consider how to manage changes to social reactions and sexual relationships that may occur.
Study NCT03978949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Licheniformis
Description: Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
Study NCT03978949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
Study NCT01684930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training
Description: The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
Study NCT01684930 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training
Description: The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
Study NCT00383292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasisulam
Description: Tasisulam dose is dependent on participant's height, weight, and gender and is adjusted to target a specific Cmax based on participant laboratory parameters. Tasisulam is administered intravenously every 28 days until disease progression or other criteria for participant discontinuation are met.
Study NCT04594122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improve hygiene practice of pork sellers
Description: includes 5 keys actions (Handbook) and provision of equipment incentive and training on good hygiene practices, branding, and certification
Study NCT01508221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trental
Description: 400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months
Study NCT01508221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months
Study NCT03792230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Video group receive body mechanic education via CD material,
Study NCT03792230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brochure
Description: Brochure group receive body mechanic education via written material (brochure)
Study NCT04190199 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Cross-sectional only
Study NCT02708446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: 200mg oral mifepristone to both study arms
Study NCT02708446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buccal misoprostol
Description: doses of buccal misoprostol every 3 hours beginning 24 hours after mifepristone
Study NCT02708446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual misoprostol
Description: doses of sublingual misoprostol every 3 hours beginning 24 hours after mifepristone
Study NCT00442741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone
Study NCT00442741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone + Omeprazole
Study NCT04371705 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes using ultrasound guide.
Study NCT04371705 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: placebo
Study NCT04311515 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Tau Positron emission tomography (PET)
Description: Tau PET imaging enables the longitudinal assessment of the spatial pattern of tau deposition. Tau accumulates with progression of AD dementia and may be sensitive to disease related changes, particularly those due to intervention with a drug thought to work through a tau related mechanism. Quantitative assessments will be utilized to evaluate the target engagement and pharmacological effects of PU-AD after 6 months of treatment
Study NCT00157209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single low dose cyclophosphamide
Description: A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
Study NCT04311515 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Tau Positron emission tomography (PET)
Description: Tau PET imaging enables the longitudinal assessment of the spatial pattern of tau deposition. Tau accumulates with progression of AD dementia and may be sensitive to disease related changes, particularly those due to intervention with a drug thought to work through a tau related mechanism. Quantitative assessments will be utilized to evaluate the target engagement and pharmacological effects of PU-AD after 6 months of treatment
Study NCT04311515 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fluorodeoxyglucose (FDG) Positron emission tomography (PET)
Description: Measurement of neuronal function with FDG PET can help to understand the relationship between target engagement and potential clinical effects. FDG PET will be acquired using stringent quality control. Since glucose metabolism captures all neuronal activity, in order to isolate effects due to treatment, patients will be maintained in a consistent state during the tracer uptake period. Subject motion during image acquisition will be minimized and monitored. Images will be quality controlled, processed, and measured quantitatively using methods that maximize signal to noise associated with technical and physiologic variability
Study NCT04311515 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Fluorodeoxyglucose (FDG) Positron emission tomography (PET)
Description: Measurement of neuronal function with FDG PET can help to understand the relationship between target engagement and potential clinical effects. FDG PET will be acquired using stringent quality control. Since glucose metabolism captures all neuronal activity, in order to isolate effects due to treatment, patients will be maintained in a consistent state during the tracer uptake period. Subject motion during image acquisition will be minimized and monitored. Images will be quality controlled, processed, and measured quantitatively using methods that maximize signal to noise associated with technical and physiologic variability
Study NCT04311515 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cerebrospinal fluid (CSF) Biomarkers
Description: A broad set of biomarkers are being assessed in this study to indicate whether this treatment is able to impact multiple pathways associated with AD related to neurodegeneration
Study NCT04311515 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Cerebrospinal fluid (CSF) Biomarkers
Description: A broad set of biomarkers are being assessed in this study to indicate whether this treatment is able to impact multiple pathways associated with AD related to neurodegeneration
Study NCT04311515 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood Biomarkers
Description: Changes in blood biomarkers may be observable if treatment affects cerebral amyloidosis and loss of nerve cells
Study NCT04311515 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Blood Biomarkers
Description: Changes in blood biomarkers may be observable if treatment affects cerebral amyloidosis and loss of nerve cells
Study NCT03060278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help materials
Description: Self-help smoking cessation materials.
Study NCT03060278 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help materials
Description: Self-help smoking cessation materials.
Study NCT01262885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablet
Study NCT04311515 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rating Scales
Description: Alzheimer's Disease composite score (ADCOMS+), CDR sb, Alzheimer's Disease Assessment Scale Cognitive (ADAS cog), Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS ADL), Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale Cognitive (ADAS-COG 12)
Study NCT02336945 — intervention group
Intervention type: DEVICE
Intervention: Abbott Sensor Based Glucose Monitoring System-Professional
Description: Subjects will wear 2 glucose sensors while going about daily activities and adhering to establish diabetes treatment plan. This is not a treatment study.
Study NCT00371436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Audiologic Tinnitus Management
Description: The five levels of progressive intervention are: (1) triage; (2) audiologic evaluation; (3) group education; (4) tinnitus evaluation; and (5) individual management.
Study NCT00371436 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Usual Care
Description: Typical audiologic care that would be received in a VA Audiology Clinic.
Study NCT01469728 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-awake VATS talc pleurodesis
Description: Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
Study NCT01469728 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake VATS talc pleurodesis
Description: Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
Study NCT02304393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
Study NCT03060278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: Participants who smoke >10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg nicotine patches. Participants who smoke \< 10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
Study NCT03060278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch
Description: Participants who smoke >10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg nicotine patches. Participants who smoke \< 10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
Study NCT03060278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered automated treatment
Description: Tailored video clips, text and graphical messages delivered automatically each week to the participant.
Study NCT03060278 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Proactive phone counseling with a Certified Tobacco Treatment Counselor
Study NCT02289794 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: E.coli bioconjugate vaccine
Description: Single dose, intramuscular injection (0.5 mL)
Study NCT04311515 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rating Scales
Description: Alzheimer's Disease composite score (ADCOMS+), CDR sb, Alzheimer's Disease Assessment Scale Cognitive (ADAS cog), Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS ADL), Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale Cognitive (ADAS-COG 12)
Study NCT04311515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PU-AD
Description: PU-AD 30mg daily for 6mos
Study NCT04311515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 30mg daily for 6mos
Study NCT01005966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride Toothpaste
Description: Test product
Study NCT01005966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amine Fluoride Toothpaste
Description: Test product
Study NCT01005966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate/Sodium Fluoride Toothpaste
Description: test product
Study NCT01005966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo and washout treatment
Study NCT01005966 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo and washout treatment
Study NCT01005966 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 675 ppmf toothpaste
Description: dose response
Study NCT03616782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib 3mg on day 1, 8, 15 q 4 weeks for 24 months or until progression
Study NCT02304393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selicrelumab
Description: Selicrelumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
Study NCT00983125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Addition of a non-labeled drug (clonidine) in one of the two arm of the study, with randomisation.~To compare the effects of a systematic addition of clonidine (150 µg added in the solution bag) in the local anesthetic solution), versus no addition, on the quality of analgesia for labour.
Study NCT00983125 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clonidine
Description: Addition of a non-labeled drug (clonidine) in one of the two arm of the study, with randomisation.~To compare the effects of a systematic addition of clonidine (150 µg added in the solution bag) in the local anesthetic solution), versus no addition, on the quality of analgesia for labour.
Study NCT01654666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
Study NCT01654666 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic preconditioning
Description: Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
Study NCT01654666 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Artery Stenting
Description: Carotid Artery Stenting is an invasive therapy of carotid artery stenosis.
Study NCT03409237 — intervention group
Intervention type: DRUG
Intervention: Mannitol
Description: Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity \<320.
Study NCT03409237 — intervention group
Intervention type: DRUG
Intervention: Hypertonic saline solution
Description: Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity \<320.
Study NCT01756027 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System providing one treatment per cheek
Description: Focused ultrasound energy delivered below the surface of the skin per cheek.
Study NCT01756027 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System providing two treatments per cheek
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT01306266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rizatriptan
Description: initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo. Drug is to be taken at onset of a moderate or severe headache
Study NCT01306266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg at onset of a moderate or severe headache.
Study NCT03693417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated circuit on
Description: Heated circuit will be turned on.
Study NCT03693417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated circuit off
Description: Heated circuit will be turned off.
Study NCT03298542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive subcutaneous golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
Study NCT03298542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to golimumab.
Study NCT01644682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IWFPL
Description: Indoor house walls and floors will be plastered with lime (a traditional method known in the study areas) including treatment of outdoor breeding places with lime and bleaching powder to inhibit sandfly breeding
Study NCT01644682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IDWL
Description: Install durable wall lining containing deltamethrin to kill immature stage and as well as adult sand flies
Study NCT02289794 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, intramuscular injection (0.5 mL)
Study NCT01356459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Border Dressing
Description: Soft silicone self adherent dressing
Study NCT01186055 — intervention group
Intervention type: BEHAVIORAL
Intervention: Smoking Cessation Counseling
Description: Participants shall all receive 8 weeks (6 weeks) of group or individual counseling during their quit attempt.
Study NCT00077324 — intervention group
Intervention type: GENETIC
Intervention: proteomic profiling
Study NCT00077324 — intervention group
Intervention type: OTHER
Intervention: surface-enhanced laser desorption/ionization-time of flight mass spectrometry
Study NCT00077324 — intervention group
Intervention type: PROCEDURE
Intervention: biopsy
Study NCT00077324 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Study NCT04022252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cheese dental laser
Description: 810 nm GaAlAs diode laser device
Study NCT04022252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse
Description: 850 nm LED (light emitting diode)
Study NCT04022252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 810 nm GaAlAs diode laser device
Study NCT04169867 — intervention group
Intervention type: BIOLOGICAL
Intervention: Collection of stool samples
Description: Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
Study NCT01654666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting
Description: Carotid Artery Stenting is an invasive therapy of carotid artery stenosis.
Study NCT01654666 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Carotid Artery Stenting
Description: Carotid Artery Stenting is an invasive therapy of carotid artery stenosis.
Study NCT03748628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-305
Description: \[14C\]EDP-305
Study NCT00648765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagrelide Hydrochloride Capsules 1 mg
Description: 1mg, single dose fed